CHEST® Resource Center
- Figure 31
SERVE-HF Trial Results 3
FIG. 31: The results of the SERVE-HF trial led to the conclusion that this ASV device should not be used in heart failure patients with a low LVEF (≤45%) and with moderate-to-severe CSA, and that any such patient already on this device should be removed from it. In addition, it was concluded that ASV in general should not be used in heart failure patients with low LVEF and CSA except in the setting of a randomized clinical trial, such as the ADVENT Trial. However, because of the high crossover rate in the SERVE-HF control cohort, per protocol results are needed to establish whether patients were dying while using ASV or not, and those data have yet to become available.
Bradley D. Chest 2016;00.
